טוען...
Orally administered saccharide-sequestering nanocomplex to manage carbohydrate metabolism disorders
Excessive carbohydrate intake is linked to the growing prevalence of diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. α-Glucosidases inhibitor, the only Food and Drug Administration–approved drug for limiting the absorption of polysaccharides and disaccharides, is ineffective for mon...
שמור ב:
| הוצא לאור ב: | Sci Adv |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Association for the Advancement of Science
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8011972/ https://ncbi.nlm.nih.gov/pubmed/33789906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.abf7311 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|